Regulations.gov document
Tab 4 - REGENXBIO Response to NGT Request for Redetermination re: Citizen Petition from…
Supporting & Related Material · FDA-2021-P-1334 · posted Dec 22, 2021
Key facts
| Document ID | FDA-2021-P-1334-0006 |
|---|---|
| Title | Tab 4 - REGENXBIO Response to NGT Request for Redetermination re: Citizen Petition from Hogan Lovells US LLP on behalf of Novartis Gene Therapies, Inc. |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-P-1334 |
| Posted | Dec 22, 2021 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: